Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size.

Yumei Ye,Kyle T. Keyes,Chong F. Zhang,Jose R. Perez-Polo,Yu Lin,Yochai Birnbaum

Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size.

2010

Yumei Ye
Kyle T. Keyes
Chong F. Zhang
Jose R. Perez-Polo
Yu Lin
Yochai Birnbaum

Purpose We assessed the effects of TAK-491 (a newly designed potent and selective ARB) alone and in combination with pioglitazone (PIO) on myocardial infarct size (IS).

Keywords:

Pioglitazone
Nitric oxide synthase
Angiotensin receptor
Agonist
Myocardial infarction
Pioglitazona
Diabetes mellitus
Internal medicine
Cardiology
Medicine
coronary heart disease
infarct size
myocardial disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations